Close Menu

NEW YORK – The European Commission has approved atezolizumab (Roche's Tecentriq) in combination with chemotherapy for patients with PD-L1-positive, unresectable, locally advanced triple-negative breast cancer, Roche said today.

Simultaneously, the company announced that the Ventana PD-L1 (SP142) Assay had garnered CE marking for this indication. The test may now be used in Europe to identify patients who express PD-L1 in 1 percent or more tumor-infiltrating immune cells, and who are likely to benefit from atezolizumab.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.